The Tungsten+PLUS™ platform delivers comprehensive downstream services, including MFP claims reconciliation, dispute resolution, and compliance-ready workflows. The platform provides Health Systems ...

Only a week after calling it quits on a court-halted pilot program, the Trump administration is already revving the engine on how it could test out a rebate model for the 340B Drug Discount program | ...

The program was meant to help hospitals provide for poor patients by offering drug savings. But critics say a Texas company has turned it into a big business, driving up costs for patients and ...

The Department of Health and Human Services Feb. 13 issued a request for information on a new 340B rebate model program.

On Dec. 29, 2025, a federal judge in Maine temporarily blocked the Department of Health and Human Services from implementing the 340B rebate pilot.

The Trump administration agreed to drop a controversial pilot that would have allowed drugmakers to give post-sales rebates ...

The Department of Health and Human Services Feb. 5 in a court filing said it would scrap its current 340B Rebate Model Pilot Program and potentially restart the administrative process for such a ...

HHS is weighing whether to redesign its 340B rebate model pilot program after two federal court rulings blocked its implementation and the agency formally agreed to abandon the initiative. On Feb. 13, ...

HHS drop 340B rebate pilot following federal court rulings and plans to remand the program to HRSA for further review.

HHS is scrapping its proposed 340B rebate pilot after hospitals sued to stop it. Providers say the plan would have created cash flow problems and administrative burdens that threatened safety-net care ...

The original goal of the 340B drug discount program was to allow qualified providers to “stretch federal resources as far as possible reaching more eligible patients and providing more comprehensive ...

Facilities and programs known as 340B-eligible "covered entities" routinely provide prescription drugs regardless of a patient's ability to pay. However, drugs purchased at 340B prices can be ...